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OBJECTIVES: Highly active antiretrovial therapy (HAART) is a mainstay of 
treatment for patients with Human Immunodeficiency Virus (HIV). Given that 
lower HAART pill burdens have been shown to be associated with an increased 
duration of initial therapy, there is a need to understand the effect of daily pill 
burden on the duration of the initial regimen. The objective of this study was to 
estimate the effects of daily pill burden on the time to discontinuation of the 
initial HAART regimen. METHODS: A retrospective cohort design was used 
where adult, female, HIV-positive patients initiating therapy at the study clinic 
were included. A Kaplan-Meier curve was generated and a Cox proportional 
hazards model was developed to assess the impact of patient, regimen, and 
demographic characteristics on the hazard of discontinuation of the initial 
regimen. RESULTS: A total of 498 charts were reviewed, yielding a cohort of 115 
adult female patients who initiated HAART at the study clinic. All study subjects 
were followed up from the initiation of HAART to treatment discontinuation. 
Patients treated with a 1 pill/day regimen had a significantly longer time to 
discontinuation than regimens of 2+ pills/day (mean duration of initial therapy 
1574.97 days vs. 977.48 days, respectively, p=0.003). Compared to 1 pill/day 
regimens, 2+ pills/day regimens were associated with a higher hazard of 
discontinuation (hazard ratio (HR) =3.44with 95% confidence interval (CI) = 1.25, 
9.48). Higher viral load and patients without insurance were also found to be 
significantly associated with higher hazards of discontinuation. CONCLUSIONS: 
The 1 pill/day regimen in the initial HAART treatment was associated with a 
lower hazard of discontinuation than any other regimen used.  
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OBJECTIVES: Monitoring transmitted drug resistance can inform national 
treatment recommendations, but U.S. data from patients initiating antiretroviral 
therapy (ART) are few. METHODS: Using data from HIV Outpatient Study (HOPS) 
participants from 10 U.S. HIV clinics diagnosed with HIV infection in 1999 or later 
and the International AIDS Society (IAS) December 2010 guidelines, we assessed 
the frequency of major ART resistance mutations in isolates from patients who 
underwent genotypic resistance testing (GT) before initiating ART. We used 
logistic regression to assess factors associated with having undergone GT and 
with harboring major IAS resistance. RESULTS: Among 1,484 eligible patients, 
711 (47.9%) had GT before first ART, increasing from 15.2% in 1999-2002 to 71.5% 
in 2009-2011 (p<0.001). During 1999-2011, patients who had GT were more likely 
to have been men who have sex with men, to have had CD4+ cell count >200 
cells/mm3, and to have had their first HOPS visit in 2003 or later (all p<0.05). Of 
695 (97.7%) patients with evaluable GT results, 114 (16.4%) had a major IAS-
defined mutation; mutations to nucleoside reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors and protease inhibitors were present, 
respectively, in 8.9%, 7.8% and 3.2% of patients. Four (0.6%) patients had triple-
class resistance and one patient had resistance to T-20, a drug in a novel fusion 
inhibitor class. We found no evidence of a temporal increase in the frequency of 
any major IAS mutation (13.2% in 1999-2002 to 17.5% in 2009-2011, p = 0.22) or in 
the frequency of mutations to any of the three main drug classes. 
CONCLUSIONS: During 1999-2011, GT use for ART-naive patients became more 
common without evidence of increases in frequency of transmitted HIV 
resistance in our large heterogeneous HIV cohort.  
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OBJECTIVES: To assess the effectiveness of the rotavirus monovalent vaccine in 
Colombia. METHODS: A hospital based case-control study was carried out. Cases 
were positive rotavirus diarrhea patients admitted to emergency departments in 
seven health care institutions across the country. Controls were non-rotavirus 
diarrhea patients admitted to emergency the department in those institutions. 
Vesikari scale was estimated to assess effectiveness of the vaccine against severe 
diarrhea. Multivariable analysis was made with logistic regression. A p-value 
<0.05 was considered statistically significant. RESULTS: A total of 60 cases and 
337 controls were used for analysis. Effectiveness of two-dose vaccination was 
46.8% (95% Confidence Interval [95%CI], -29.6 to 78.3). Effectiveness of two-dose 
vaccination applied at recommended age (less than 8 months of age) was 55.8% 
(95%CI, 7.3 to 78.9). Two-dose vaccination effectiveness in the multivariable 
analysis was 62.6% (95%CI, 0.30 to 85.9), and if applied at recommended age was 
71.9% (95%CI, 35.5 to 87.8). Results showed an effectiveness decline after 9 
months of vaccination. Effectiveness was 69% (95%CI, 26.7 to 86.9) during the 
nine months after vaccination, and 40.5% (95%CI, -31.3 to 73.1) after those nine 
months. CONCLUSIONS: Rotavirus vaccination with the monovalent vaccine was 
effective in Colombia, if applied to recommended age.  
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OBJECTIVES: To assess the clinical effectiveness of combined therapy with 
interferon (pegylated or non-pegylated) and ribavirin versus interferon alone for 
the treatment of chronic HCV in adult patients. METHODS: We used standard 
HTA methods as PICOs, comparative analysis, descriptive epidemiology to 
evaluate a clinical effectiveness of the anti HCV treatment in several respectable 
trials. Studies eligible for inclusion were systematic reviews of randomized 
controlled trials (RCTs), RCTs, HTA reports, economic evaluations, high quality 
primary studies (preferably RCTs). Preference was given to references published 
in the English or Russian languages and preferably published within the past 10 
years (2002 forward). RESULTS: All subgroups of included trials consisted of 
13,331 patients with chronic hepatitis C without HIV infection or liver 
transplantation with diagnosed on the presence of serum hepatitis C virus RNA 
plus elevated serum transaminase activity for more than 6 months or chronic 
hepatitis documented by liver biopsy. All of the included studies detected the 
clinical efficacy of combined therapy of IFN + RBV. According to trials, patients 
with non-1 genotype had higher virological response rates than patients with 
genotype 1. Genotype 1 patients had significantly higher SVR rates when treated 
for 48 weeks compared with 24 weeks. PEG and four IFN trials reported alanine 
aminotransferase (ALT) response rates after treatment. Sustained biochemical 
response was greater for IFN + RBV compared with IFN monotherapy or IFN with 
placebo, reaching significance in two trials and borderline significance in one 
trial. CONCLUSIONS: The clinical effectiveness of the combined therapy with 
ribavirin and interferon is convincing. However, using the ribavirin in 
combination with interferon (pegylated or non-pegylated) can not be final, owing 
to the many adverse effects. Assessment of the recovery of patients by the 
sustained virologic response should not be so pragmatic, because it is only a 
change of the "surrogate" criterias.  
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OBJECTIVES: The continuing spread of antimicrobial resistance, due to 
uncontrolled antibiotic use, is a major public health problem worldwide. The aim 
of this study is to make an inventory of the antimicrobials for systemic use in 
the home pharmacies of the urban and rural populations in South Ba ka District, 
Serbia. METHODS: This study was performed in 6 months period (February - July 
2010) on a sample of 208 households (108 in urban and 100 in rural communities) 
in South Ba ka District, Serbia. The families were chosen randomly and the data 
were collected by checking the inventory of antibiotics in the home pharmacies. 
RESULTS: The total number of drug packages present in 208 households was 
2221. Every other household had at least one package belonging to J01 class 
stored at home(51.0% in rural and 65.8% in urban households). A total number of 
89 packages belonging to J01 class were present in the surveyed rural families 
which constitutes 8.9% of total stored drugs. In urban families, the number of 
packages of antibiotics was 113 (9.3% of total drugs stored). The average number 
of antibacterial drug packages per household was 0.9 (range: 0-4) in rural and 1.0 
(range: 0-6) in urban families. The most frequent antibacterial agents both in 
rural and urban households was amoxicillin (20.1%), followed by cefalexin 
(14.8%) and amoxicillin+clavulanic acid (14.2%). CONCLUSIONS: According to this 
study, antibiotics are widely stocked among both rural and urban communities 
in South Ba ka District, Serbia, which requires further investigation of this 
practice.  
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OBJECTIVES: The aim of the study was to analyze of use of anti-infective drugs 
for systemic administration (ATC-group J) in Serbia in 2011 year. METHODS: Data 
about use of anti-infective drugs for systemic administration in Serbia in 2011 
was taken from the Agency for Drugs and Medical Devices of Serbia. RESULTS: 
Use of all drugs in Serbia in 2011 was 1,104.57 DDD/1000 inhabitants/day. ATC-
group J was on the seventh place according to amount of DDDs with 27.35 
DDD/1000 inh/day or 2.48% of total consumption. According to the funding 
spent, this group was on the second position with 77,800,748.63€. In this group, 
subgroup with highest consumption were antibacterial drugs for systemic use 
(subgroup J01), with 26.68 DDD/1000 inh/day or 97.55% of total use in group J. 
This subgroup takes first place in funding spent with 52,801,780.13€ or 67.87% of 
total expended finances in this group in 2011. Beta-lactam antibacterial drugs 
with 14.98 DDD/1000 inh/day or 56.15% were drugs with highest use in this 
subgroup, macrolides and lincosamides were at second place with 5.11 DDD/1000 
inh/day or 19.15%, while on the third place were quinolones with 2.66 DDD/1000 
inh/day or 9.97% of total drug utilization inside this subgroup. Funding spent on 
beta-lactam antibacterial drugs was 29,522,197.18€ or 55.91%, macrolides and 
lincosamides 10,811,308.09€ or 20.48%, and for quinolones 6,286,373.19€ or 
11.91% of total funding spent for subgroup J01 in 2011 year. CONCLUSIONS: In 
comparison to 2010 spending of group J in Serbia in 2011 year was increased for 
